Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis

Objectives: To evaluate and compare the efficacy, safety, and cost of nine Chinese patent medicines (CPMs) combined with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in treating early diabetic kidney disease (DKD). Design: Systematic review and network meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiarong, Zhang, Xuehan, Xu, Gaosi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441488/
https://www.ncbi.nlm.nih.gov/pubmed/36071841
http://dx.doi.org/10.3389/fphar.2022.939488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441488/
https://www.ncbi.nlm.nih.gov/pubmed/36071841
http://dx.doi.org/10.3389/fphar.2022.939488

Ejemplares similares